Cure Alzheimer's Fund's Dr. Rudy Tanzi will appear on PBS's NOVA scienceNOW on Wednesday, July 2, to discuss genetic testing and it's impact on Alzheimer's and other hereditary diseases.

Click here for more details about the show

Cure Alzheimer's Fund's Dr. Rudy Tanzi discusses the latest Alzheimer's research on flavonoids and new drugs being developed to prevent and slow the disease on World Health News Today.

 Please click here to view the first segment of the interview

Two new Alzheimer's drugs, Flurizan (Myriad) and Bapineuzumab (Wyeth/Elan), failed clinical trials. Cure Alzheimer's Fund's Dr. Rudy Tanzi offers some prespective on these drugs.

Read the CNN Money Myriad (Flurizan) press release here

Read the ABC News report on Flurizan

Read the Wyeth/Elan bapineuzumab press release here

Clinical Trial Update
By Dr. Rudolph Tanzi, Massachusetts General Hospital

The results of two clinical trials for Alzheimer’s disease (AD) based on the “amyloid (Αβ) hypothesis of AD” were recently released -- flurizan (Myriad) and bapineuzumab (Wyeth/Elan).  These therapies are aimed at slowing disease progression by curbing the accumulation of Αβ in the brain.

Washington, May 14, 2008 – Mapping the sequence of the genes susceptible to Alzheimer’s disease provides a novel avenue for potential treatment while also improving the ability to predict risk for Alzheimer’s early in life, Dr. Rudolph Tanzi, chairman of the Cure Alzheimer’s Fund Research Consortium, told the Senate Special Committee on Aging at a hearing today on the disease.    

Two papers, supported in part by Cure Alzheimer’s Fund,  have just been published in two leading research journals. The findings show links between certain kinds of anesthesia and pathological features of Alzheimer’s disease. 

This Science Update gives you an overview about what is know about the science behind Alzheimer’s disease and how at Cure Alzheimer's Fund we are funding research to get to a cure as quickly as possible.

Download the document >